Sound Income Strategies LLC Purchases 47,116 Shares of Pfizer Inc. $PFE

Key Points

• Sound Income Strategies LLC has increased its holdings in Pfizer Inc. by 6.0%, acquiring an additional 47,116 shares during Q2, bringing its total to 838,069 shares worth approximately $20.3 million.
• Pfizer reported $0.78 EPS for the last quarter, exceeding estimates, with a revenue of $14.65 billion, marking a 10.3% increase compared to the previous year.
• As of now, analysts rate Pfizer with an average rating of "Hold" and a consensus price target of $28.12, with recent adjustments from major firms like Morgan Stanley and Bank of America.

Sound Income Strategies LLC increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 838,069 shares of the biopharmaceutical company's stock after buying an additional 47,116 shares during the quarter. Pfizer accounts for about 1.2% of Sound Income Strategies LLC's investment portfolio, making the stock its 21st largest position. Sound Income Strategies LLC's holdings in Pfizer were worth $20,315,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Pfizer by 4,183.6% during the first quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company's stock valued at $40,537,000 after purchasing an additional 1,562,396 shares in the last quarter. Cascade Investment Advisors Inc. increased its holdings in shares of Pfizer by 2.0% in the first quarter. Cascade Investment Advisors Inc. now owns 64,409 shares of the biopharmaceutical company's stock worth $1,632,000 after purchasing an additional 1,265 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its position in shares of Pfizer by 35.9% in the first quarter. Fifth Third Wealth Advisors LLC now owns 120,285 shares of the biopharmaceutical company's stock worth $3,048,000 after buying an additional 31,766 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock opened at $23.75 on Monday. The firm has a 50-day moving average price of $24.55 and a 200-day moving average price of $24.12. The firm has a market capitalization of $135.03 billion, a PE ratio of 12.63, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.